Xenetic Biosciences (NASDAQ:XBIO) Rating Reiterated by HC Wainwright

Xenetic Biosciences (NASDAQ:XBIO)‘s stock had its “neutral” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports.

Xenetic Biosciences Trading Up 0.2 %

Xenetic Biosciences stock opened at $4.08 on Tuesday. Xenetic Biosciences has a 1-year low of $2.78 and a 1-year high of $5.97. The firm’s 50 day simple moving average is $3.96 and its 200 day simple moving average is $3.98. The firm has a market capitalization of $6.29 million, a PE ratio of -1.39 and a beta of 2.29.

Xenetic Biosciences (NASDAQ:XBIO) last issued its earnings results on Tuesday, August 13th. The company reported ($0.83) earnings per share for the quarter, meeting the consensus estimate of ($0.83). Xenetic Biosciences had a negative return on equity of 43.40% and a negative net margin of 182.99%. The company had revenue of $0.73 million during the quarter, compared to analysts’ expectations of $0.54 million. Research analysts forecast that Xenetic Biosciences will post -0.96 earnings per share for the current year.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.